Upcoming Event
Sidoti & Company Spring 2019 Conference
Upcoming Event
Spring Investor Summit 2019
JW Marriott Essex House, New York, NY
Upcoming Event
2019 Annual Meeting of the Shareholders
The Offices of Lowenstein Sandler LLP at 1251 Avenue of the Americas, New York, New York 10020
Latest Financial Results
Dec 31, 2018
Stock Information
Symbol
Nasdaq: TNXPPrice
Change
MKT Cap
Volume
52 week Low/High
Day Low/High
Company Overview
Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense through potential medical counter-measures. Tonix's lead product candidate, Tonmya, or TNX-102 SL, is in Phase 3 development as a bedtime treatment for PTSD. Tonix is also developing TNX-102 SL as a bedtime treatment for agitation in Alzheimer's disease. A Phase 2 IND (Investigational New Drug) application was submitted in March 2018 after completion of a successful pre-IND meeting with the FDA. TNX-601 (tianeptine oxalate) is in the pre-IND application stage, also for the treatment of PTSD but designed for daytime dosing. Tonix's lead biologic candidate, TNX-801, is a potential smallpox-preventing vaccine based on a live synthetic version of horsepox virus, currently in the pre-IND application stage.
IR Contact Information
Investor Relations
TONIX Pharmaceuticals
investor.relations@tonixpharma.com
Transfer Agent
vStock Transfer
77 Spruce Street
Suite 201
Cedarhurst, NY 11516
T: 212-828-8436
www.vstocktransfer.com